PHARMACOLOGY OF OMEGA-3 FATTY ACIDS IN MAN

来自海洋油的omega-3脂肪酸对健康的潜在好处是 正在进行深入的调查，一些最有希望的领域是 改善血管疾病和降低血压的那些。许多. Omega-3脂肪酸的作用被归因于 二十烷类化合物的产生，但很少有研究在人体内测量过 这些物质的合成和相关鱼油诱导的改变 功能性的。在降低血压的同时，omega-3脂肪酸减少 人和备用者血管舒缩剂/促凝血素合成 甚至增加血管扩张剂/抗聚集前列环素的水平。他们的 对前列腺素E_2和其他二十烷类化合物产生的影响 在肾功能和血管紧张性方面的重要性在人类和NO中没有定义 钠平衡、肾素或其他因素对omega-3影响的研究 已执行卷状态。 最近，人们注意到使用β-受体阻滞剂治疗高血压 利尿剂在降低心脏病风险方面的效果不如 预测到了。这可能是由于这些药物在中国的不良影响。 升高血浆极低密度脂蛋白，降低高密度脂蛋白。然而，omega-3脂肪酸有 已发现在降低血脂的同时对血脂有相反的影响 血压，所以它们有可能成为有用的辅助工具 治疗高血压的方法。 这项拟议的研究将定义 欧米茄-3脂肪酸的降压作用及其对血管紧张素转换酶的影响 黑人和女性中的高血压。内源合成中的变化 摄取omega-3期间前列腺素、血栓烷和新型环氧化物的变化 将使用最先进的GC/MS方法进行测量，并与 血压、血管电容和阻力的变化以及 在血管紧张素调节和电解质排泄中的作用 研究对象。抗高血压药对血脂变化的影响 对更严重高血压患者的药物也将进行研究。这 综合和集中的方法将定义哪些高血压患者可能 Omega-3脂肪酸补充剂的益处或恶化及其机制 通过它来实现这一点。

The potential health benefits of omega-3 fatty acids from marine oils are being intensively investigated and some of the most promising areas are those of ameliorating vascular disease and lowing blood pressure. Many of the effect of omega-3 fatty acids have been attributed to changes in eicosanoid production, but few studies in man have measured the in vivo synthesis of these substances and related fish oil-induced alterations to functional ones. While lowering blood pressure, omega-3 FA reduce vasoconstrictor/proaggregatory thromboxane synthesis in man and spare or even increase that of vasodilator/anti-aggregatory prostacyclin. Their effects on the production of prostagladin E2 and other eicosanoids important in renal function and vascular tone are not defined in man and no studies on omega-3 effects in subjects with known sodium balance, renin or volume status have been performed. Recently, it has been noted that treating hypertension with beta-blockers and diuretics has not yielded as great a reduction in cardiac risk as predicted. This may be due to unfavorable effects of these drugs in elevating plasma VLDL and lowering HDL. Omega-3 fatty acids, however, have been found to have the opposite effects on plasma lipids while lowering blood pressure, so they have the potential for being useful adjunctive therapy in treated hypertension. The proposed research will define the dose-response relationship in the hypotensive actions of omega-3 fatty acids and assess their effect on hypertension in blacks and women. Alteration in the endogenous synthesis of prostaglandins, thromboxanes and novel epoxides during omega-3 ingestion will be measured with stat-of-the-art GC/MS methods and correlated with changes in blood pressure, vascular capacitance and resistance, as well as in angiotensin modulation and electrolyte excretion in well-defined subjects. The effects on plasma lipid changes due to anti-hypertensive drugs in more severely hypertensive patients will also be studied. This integrated and focussed approach will define which hypertensives might benefit or be worsened by omega-3 fatty acid supplements and the mechanisms by which this would occur.